HLS Therapeutics (HLS) Aandelenoverzicht
HLS Therapeutics Inc. is een gespecialiseerd farmaceutisch bedrijf dat farmaceutische producten verwerft en verkoopt voor de behandeling van psychiatrische stoornissen, het centrale zenuwstelsel en hart- en vaatziekten in Canada, de Verenigde Staten en internationaal. Meer informatie
| Sneeuwvlok Score | |
|---|---|
| Waardering | 3/6 |
| Toekomstige groei | 4/6 |
| Prestaties in het verleden | 0/6 |
| Financiële gezondheid | 3/6 |
| Dividenden | 0/6 |
HLS Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
HLS Therapeutics Inc. Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | CA$4.19 |
| 52 Week Hoogtepunt | CA$5.77 |
| 52 Week Laag | CA$4.00 |
| Bèta | 0.86 |
| 1 maand verandering | 1.21% |
| 3 maanden verandering | -9.89% |
| 1 Jaar Verandering | -15.69% |
| 3 jaar verandering | -33.49% |
| 5 jaar verandering | -75.38% |
| Verandering sinds IPO | -63.85% |
Recent nieuws en updates
Narratiefupdate • Jun 23
HLS: Future Upside Will Depend On Executing Reaffirmed 2026 Earnings Guidance
Analysts have adjusted their CA$5 price target on HLS Therapeutics in light of updated assumptions for revenue growth, profit margins, and future P/E. This reflects a refined view of the stock's potential value.
Narratiefupdate • Jun 07
HLS: Future Execution Risks Will Restrain Benefits Of New Franchise And Hold Stance
Analysts have updated their view on HLS Therapeutics with a refined fair value of CA$4.49 per share. This is supported by refreshed assumptions on revenue growth, profit margins, discount rate and future P/E that align with recent Street price targets in the CA$4.45 to CA$5.00 range.Narratiefupdate • May 24
HLS: Future Upside Will Depend On Delivering New 2026 Revenue Guidance
Analysts have modestly adjusted their CA$ price target on HLS Therapeutics, with models reflecting a fair value estimate holding close to CA$12.00, supported by recent Hold-rated coverage and slightly lower Street targets around CA$4.45 to CA$5.00. Analyst Commentary Recent Street research on HLS Therapeutics has centered on Hold ratings paired with price targets in the CA$4.45 to CA$5.00 range.Recent updates
Narratiefupdate • Jun 23
HLS: Future Upside Will Depend On Executing Reaffirmed 2026 Earnings Guidance
Analysts have adjusted their CA$5 price target on HLS Therapeutics in light of updated assumptions for revenue growth, profit margins, and future P/E. This reflects a refined view of the stock's potential value.Narratiefupdate • Jun 07
HLS: Future Execution Risks Will Restrain Benefits Of New Franchise And Hold Stance
Analysts have updated their view on HLS Therapeutics with a refined fair value of CA$4.49 per share. This is supported by refreshed assumptions on revenue growth, profit margins, discount rate and future P/E that align with recent Street price targets in the CA$4.45 to CA$5.00 range.Narratiefupdate • May 24
HLS: Future Upside Will Depend On Delivering New 2026 Revenue Guidance
Analysts have modestly adjusted their CA$ price target on HLS Therapeutics, with models reflecting a fair value estimate holding close to CA$12.00, supported by recent Hold-rated coverage and slightly lower Street targets around CA$4.45 to CA$5.00. Analyst Commentary Recent Street research on HLS Therapeutics has centered on Hold ratings paired with price targets in the CA$4.45 to CA$5.00 range.Narratiefupdate • May 04
HLS: Future Upside Will Depend On Executing Refined Earnings Outlook
Analysts have trimmed their price target on HLS Therapeutics to CA$4.45 from CA$4.75, reflecting updated views on the company that feed into revised assumptions regarding growth, margins and future P/E. Analyst Commentary Recent research updates on HLS Therapeutics show price targets aligning at CA$4.45, with ratings maintained rather than shifted to more negative stances.Narratiefupdate • Apr 18
HLS: Future Execution Risks Will Temper Benefits Of New Cholesterol Franchise
Analysts have trimmed their price target on HLS Therapeutics to CA$4.45 from CA$4.75, reflecting updated views on its growth profile and profitability. Analyst Commentary Bearish analysts are signaling a more cautious stance on HLS Therapeutics after the revised CA$4.45 price target.Narratiefupdate • Apr 02
HLS: Future Execution Risks Will Offset New Product And Margin Assumptions
Analysts have trimmed their price target on HLS Therapeutics to CA$4.45 from CA$4.75, reflecting updated views on the company’s revenue growth potential, profit margin outlook, and a higher assumed future P/E multiple. Analyst Commentary Bearish analysts have reacted to recent developments by trimming their price target on HLS Therapeutics to CA$4.45 from CA$4.75, while maintaining a Hold stance.Narratiefupdate • Mar 18
HLS: Future Share Performance Will Rely On Execution Against Updated Outlook
The analyst price target for HLS Therapeutics has been reduced by CA$0.30 to CA$4.45. Analysts cited updated assumptions around growth, profitability and valuation multiples as key drivers for the change.Narratiefupdate • Mar 03
HLS: Fair Outlook Will Balance Revised Profitability Assumptions And Execution Risks
Analysts have trimmed their price target on HLS Therapeutics to CA$4.72 from CA$4.76, reflecting updated assumptions around discount rates, revenue growth, profit margins, and a slightly lower future P/E multiple. Valuation Changes Fair Value: CA$ fair value estimate adjusted slightly from CA$4.76 to CA$4.72.Narratiefupdate • Feb 17
HLS: Improved Profitability Outlook Will Support Stronger Future Share Performance
Analysts now see fair value for HLS Therapeutics at about CA$11.59, slightly below the prior CA$11.79. This reflects updated assumptions around discount rate, revenue growth, profit margin and future P/E expectations.Narratiefupdate • Feb 03
HLS: Higher Profitability Outlook Will Support Upgraded Future Share Performance
Analysts have nudged their price target on HLS Therapeutics higher to C$7 from C$6, pointing to updated assumptions on revenue growth, profit margins and future P/E levels that support a slightly revised outlook for the shares. Analyst Commentary Recent Street research reflects a slightly more optimistic tone around HLS Therapeutics, with bullish analysts adjusting their models to support a higher valuation anchor for the shares.Narratiefupdate • Jan 20
HLS: Higher Profitability Outlook Will Drive Stronger Future Share Performance
Analysts have raised their price target on HLS Therapeutics to C$7 from C$6, reflecting updated views on fair value, growth expectations, profitability, and future P/E assumptions. Analyst Commentary Recent Street research points to a more constructive view on HLS Therapeutics, with bullish analysts revisiting their assumptions on fair value, growth potential, and what they are willing to pay on a P/E basis.Narratiefupdate • Jan 06
HLS: Higher Rating Outlook Will Balance Execution Risks And Near Term Guidance
Analysts lifted their price target for HLS Therapeutics to C$7 from C$6, citing updated assumptions around fair value, discount rate, revenue growth, profit margins and a lower future P/E multiple in their models. Analyst Commentary Even with the price target now set at C$7, some research commentary still reads as cautious.Narratiefupdate • Dec 14
HLS: Higher Projected Earnings Will Support Stronger Future Share Performance
Analysts have raised their price target on HLS Therapeutics by C$1 to C$7, reflecting higher projected fair value, faster expected revenue growth, and improved profit margin assumptions, despite a slightly higher discount rate and lower future P/E multiple. Analyst Commentary Bullish analysts highlight that the higher price target reflects growing confidence in HLS Therapeutics execution and earnings trajectory, even after factoring in a modestly higher risk profile.
Narratiefupdate • Nov 19
HLS: Ongoing Share Buybacks And Debt Reduction Will Drive Positive Momentum
The analyst price target for HLS Therapeutics has increased from C$6 to C$7. This reflects analysts’ confidence in the company’s improving financial performance and ongoing strategic initiatives.Analyse-artikel • Nov 16
HLS Therapeutics Inc. (TSE:HLS) Just Reported, And Analysts Assigned A CA$6.80 Price Target
The analysts might have been a bit too bullish on HLS Therapeutics Inc. ( TSE:HLS ), given that the company fell short...Narratiefupdate • Sep 25
Canadian Regulatory Approvals Will Foster A Vibrant Cardiovascular Market
Analysts have raised their price target for HLS Therapeutics to CA$7.41, citing positive impacts from share buybacks, debt reduction, and an expanding product portfolio, alongside signs of adjusted EBITDA recovery and improved operational performance. Analyst Commentary Share buybacks and debt reduction are viewed positively for capital allocation and balance sheet strength.
Nieuw narratief • Apr 07
Vascepa Sales In Canada And Cost Cuts Will Transform Prospects
Significant revenue growth is expected from Vascepa in Canada, driven by increased prescriptions and stabilizing payer mix, positively impacting revenue.Analyse-artikel • Oct 26
Are Investors Undervaluing HLS Therapeutics Inc. (TSE:HLS) By 45%?
Key Insights Using the 2 Stage Free Cash Flow to Equity, HLS Therapeutics fair value estimate is CA$6.42 Current share...Analyse-artikel • Sep 28
Pinning Down HLS Therapeutics Inc.'s (TSE:HLS) P/S Is Difficult Right Now
It's not a stretch to say that HLS Therapeutics Inc.'s ( TSE:HLS ) price-to-sales (or "P/S") ratio of 1.5x right now...Analyse-artikel • May 12
Analysts Have Lowered Expectations For HLS Therapeutics Inc. (TSE:HLS) After Its Latest Results
It's shaping up to be a tough period for HLS Therapeutics Inc. ( TSE:HLS ), which a week ago released some...Analyse-artikel • Apr 14
After Leaping 29% HLS Therapeutics Inc. (TSE:HLS) Shares Are Not Flying Under The Radar
The HLS Therapeutics Inc. ( TSE:HLS ) share price has done very well over the last month, posting an excellent gain of...Analyse-artikel • Apr 06
Here's Why HLS Therapeutics (TSE:HLS) Can Afford Some Debt
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analyse-artikel • Nov 16
Analysts Are More Bearish On HLS Therapeutics Inc. (TSE:HLS) Than They Used To Be
Market forces rained on the parade of HLS Therapeutics Inc. ( TSE:HLS ) shareholders today, when the analysts...Analyse-artikel • Sep 13
Here's Why HLS Therapeutics (TSE:HLS) Can Afford Some Debt
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analyse-artikel • May 05
Would HLS Therapeutics (TSE:HLS) Be Better Off With Less Debt?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analyse-artikel • Apr 05
HLS Therapeutics (TSE:HLS) Is Due To Pay A Dividend Of $0.05
The board of HLS Therapeutics Inc. ( TSE:HLS ) has announced that it will pay a dividend on the 15th of June, with...Analyse-artikel • Mar 20
HLS Therapeutics (TSE:HLS) Is Paying Out A Dividend Of $0.05
The board of HLS Therapeutics Inc. ( TSE:HLS ) has announced that it will pay a dividend on the 15th of June, with...Rendement voor aandeelhouders
| HLS | CA Pharmaceuticals | CA Markt | |
|---|---|---|---|
| 7D | 1.9% | -1.4% | 1.6% |
| 1Y | -15.7% | 22.2% | 29.5% |
Rendement versus industrie: HLS presteerde slechter dan de Canadian Pharmaceuticals -sector, die het afgelopen jaar een rendement van 22.2 % opleverde.
Rendement versus markt: HLS presteerde slechter dan Canadian Market, dat het afgelopen jaar een rendement van 29.5 % opleverde.
Prijsvolatiliteit
| HLS volatility | |
|---|---|
| HLS Average Weekly Movement | 3.5% |
| Pharmaceuticals Industry Average Movement | 8.8% |
| Market Average Movement | 9.4% |
| 10% most volatile stocks in CA Market | 16.3% |
| 10% least volatile stocks in CA Market | 3.6% |
Stabiele aandelenkoers: HLS heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend vergeleken met de Canadian markt.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 3% ) van HLS is het afgelopen jaar stabiel geweest.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| n/a | 85 | Craig Millian | www.hlstherapeutics.com |
HLS Therapeutics Inc. is een gespecialiseerd farmaceutisch bedrijf dat farmaceutische producten verwerft en commercialiseert voor de behandeling van psychiatrische stoornissen, het centrale zenuwstelsel en cardiovasculaire aandoeningen in Canada, de Verenigde Staten en internationaal. De belangrijkste producten van het bedrijf zijn Clozaril, een atypisch antipsychoticum voor de behandeling van symptomen van behandelingsresistente schizofrenie; en Vascepa, een icosapent ethylcapsule voor hart- en vaatziekten. Het verdeelt ook MyCare psychiatrie lab assays en MyCare Insite, een point-of-care apparaat voor het meten van medicijnniveaus bij patiënten.
HLS Therapeutics Inc. Samenvatting
| HLS fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | CA$128.54m |
| Inkomsten(TTM) | -CA$14.53m |
| Inkomsten(TTM) | CA$78.71m |
1.7x
P/S-verhouding-9.0x
Koers/WinstverhoudingIs HLS overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| HLS resultatenrekening (TTM) | |
|---|---|
| Inkomsten | US$55.74m |
| Kosten van inkomsten | US$16.15m |
| Brutowinst | US$39.59m |
| Overige uitgaven | US$49.89m |
| Inkomsten | -US$10.29m |
Laatst gerapporteerde inkomsten
Mar 31, 2026
Volgende inkomensdatum
n.v.t.
| Winst per aandeel (EPS) | -0.33 |
| Brutomarge | 71.03% |
| Nettowinstmarge | -18.46% |
| Schuld/Eigen Vermogen Verhouding | 73.5% |
Hoe presteerde HLS op de lange termijn?
Bekijk historische prestaties en vergelijkingBedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/07/27 19:13 |
| Aandelenkoers aan het einde van de dag | 2026/07/27 00:00 |
| Inkomsten | 2026/03/31 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysamodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
HLS Therapeutics Inc. wordt gevolgd door 4 analisten. 4 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| David Martin | Bloom Burton & Co. |
| Tania Armstrong-Whitworth | Canaccord Genuity |
| Michael Freeman | Raymond James Ltd. |